NVE Corporation 10-Q Summary: Quarter Ended September 30, 2007
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for NVE Corporation, a developer and seller of spintronic devices (nanotechnology relying on electron spin). The report covers the quarterly period ended September 30, 2007, and the six-month period ended on the same date. The company is an accelerated filer incorporated in Minnesota.
Key Financial Metrics
| Metric | Quarter Ended Sept 30, 2007 | Six Months Ended Sept 30, 2007 |
|---|---|---|
| Total Revenue | $5,004,620 | $9,713,903 |
| Net Income | $1,644,774 | $3,232,109 |
| Diluted EPS | $0.34 | $0.67 |
| Gross Margin | 63.0% | 66.1% |
| Operating Cash Flow (6mo) | $3,168,236 | |
| Cash & Marketable Securities | $21,031,486 (as of Sept 30, 2007) | |
| Total Debt | None reported (No long-term debt or capital lease obligations outstanding) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13.8% for the quarter and 20.9% for the six months compared to the prior year periods. This was driven primarily by a 14.2% increase in product sales for the quarter and a 25.6% increase for the six months.
- Profitability: Net income rose 28.2% for the quarter and 48.6% for the six months. Operating income increased 21.9% for the quarter and 41.3% for the six months.
- Expense Management: Research and development (R&D) expenses decreased significantly, down 45% for the quarter and 25% for the six months, attributed to the completion of specific projects. Selling, general, and administrative (SG&A) expenses increased 8% for the quarter and 21% for the six months, partly due to stock-based compensation and audit costs.
- Interest Income: Interest income surged 65% for the quarter and 80% for the six months due to a larger portfolio of interest-bearing marketable securities.
- Tax Payments: The company began paying regular cash income taxes in the second quarter of fiscal 2008 ($1.48M paid in the six months) after fully utilizing stock-based compensation deductions and tax credits.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management believes working capital is adequate for the next 12 months. The company continues to invest in capital equipment to increase production capacity.
- Legal Contingencies: A consolidated shareholder class-action lawsuit regarding alleged misrepresentations was dismissed with prejudice in July 2007. However, related derivative actions remain pending, and the company cannot determine the ultimate disposition or record a liability at this time.
- Key Risks:
- Customer Concentration: Significant revenue reliance on large customers, specifically St. Jude Medical (agreement expires Dec 31, 2009) and Avago Technologies (assigned from Agilent, agreement expires June 27, 2010). Loss of either could materially impact revenue.
- Market Risks: Approximately 70% of total assets are held in marketable securities, exposing the company to interest rate and market value fluctuations.
- Unusual Items: No unusual items were reported; the increase in SG&A was explicitly linked to standard stock-based compensation adjustments and audit compliance costs.
Investor Verification Checklist
- Verify the renewal status and terms of the Supplier Partnering Agreement with St. Jude Medical and the OEM Purchase Agreement with Avago Technologies.
- Monitor the status of the pending derivative shareholder lawsuits and potential legal expense accruals.
- Assess the sustainability of the R&D expense reduction and its impact on future product innovation.
- Review the composition of the $21M cash and marketable securities portfolio to evaluate exposure to market volatility.
- Confirm the trajectory of cash tax payments now that stock-based compensation deductions have been fully utilized.